PRESS INFORMATION BUREAU पत्र सूचना कार्यालय GOVERNMENT OF INDIA यारत सरकार

Business Line, Delhi Wednesday 17th September 2014, Page: 3 Width: 5.94 cms, Height: 4.93 cms, a4, Ref: pmin.2014-09-17.40.31

## Hetero Drugs signs up with Gilead

Hyderabad, September 16

Hetero Drugs has obtained licensing rights to manufacture and market Sofosbuvir and combination drug Ledipasvir/Sofosbuvir with approval from Gilead Sciences Inc, US. The Hyderabad-based company can market the drug in 90 countries. The drug is used for the treatment of chronic hepatitis C. The company is committed to bring hepatitis C medicines to India, where about 1.8 per cent of the population are affected by the problem. OUR BUREAU

Compon